The global multi-omics solution
for precision oncology
Indivumed GmbH was founded in 2002 by leading scientists with a drive to revolutionize cancer treatment through individualized therapy.
As a physician-led, integrated global oncology company our experts leverage the world’s premier multi-omics oncology database and highest quality biobank to develop a true picture of cancer.
Our three divisions operate holistically with one another for the generation, characterization, and analysis of biologic samples from human cancer patients.
Indivumed is headquartered in Hamburg, Germany, with a US-based subsidiary and a global clinical network.
Since its founding, Indivumed has grown exponentially, our reputation for product and service quality and relationships expanding across the globe. We are always looking to the horizon for new partnerships and methods to support the realization of our vision.
Explore the highlights of our journey:
2021 - June
Indivumed Launches nRavel™ AI Platform
2021 - May
Indivumed Joins KHR Biotec GmbH
2021 - March
Indivumed Launches Spinoff Ix Therapeutics
2020 - November
Indivumed Launches Groundbreaking AI Platform to Leverage Multi-omics Data for Discoveries in Oncology.
2020 - September
Indivumed Announces Global Expansion of Clinical Network to Grow IndivuType Database.
2020 - April
Indivumed Launches Global Oncology Alliance For Individualized Medicine (“Onco AI-Med”).
2019 – May
Indivumed launches first real multi-omics cancer platform to advance precision oncology.
2019 – April
Evotec and Indivumed announce strategic drug discovery collaboration on precision medicine for colorectal cancer.
2018 – December
Indivumed announces an International Partnership with IMCB to establish an Asian-Centric Multiomics Cancer Database for Personalized Oncology.
2018 – November
Indivumed opens the new U.S. headquarter in Frederick, MD.
2018 - January
The Salk Institute and Indivumed have established a strategic partnership to advance research in precision oncology and personalized medicine by utilizing the highest quality molecular and clinical data in cancer.
2018 - January
Investment Plan for Europe: The European Investment Bank (EIB) will provide a loan of EUR 40m to Indivumed GmbH.
2017 - August
Indivumed will collaborate with MedStar Health to advance our understanding of the molecular basis of cancer through collection and analysis of biospecimens and clinical data, making possible new individualized diagnosis and treatment of cancer.
2017 - February
Indivumed announces a partnership with the Indian Institute of Technology Madras to help develop the organization's cancer biobank and database for use in precision medicine research.
2017 - January
Indivumed announces a partnership with Northwell Health in New York, USA, to expand cancer biobanking activities with the health care provider.
2016 - March
Indivumed begins a research partnership with the Medical University of Bialystok.
2016 - February
Indivumed announces a partnership with the University of Rochester Medical Center in New York, USA, to create a new human tissue and tumor biobank.
2014 - July
Indivumed and Geisinger Health System, USA, partner for personalized medicine initiative in the US.
2013 - October
Indivumed sells Inostics to the Sysmex Corporation.
2011 - December
IndivuTest GmbH is founded as a wholly owned subsidiary of Indivumed to provide individualized diagnostics to oncologists and cancer patients as support to select the next beneficial therapy.
2010 - April
Indivumed becomes certified according to ISO 9001:2008.
2009 - October
Indivumed becomes a clinical research partner in the newly founded Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown University, USA.
2009 - November
Indivumed is awarded and funded by the NCI as a research partner to study factors impacting tissue quality.
2008 - November
Indivumed moves to its new facility located at the Center for Innovative Medicine (CIM) in Hamburg, Germany.
2008 - September
Together with renowned cancer researcher and HHMI investigator, Dr. Bert Vogelstein (Johns Hopkins University), Indivumed founds the diagnostics company Inostics GmbH.
2008 - July
Indivumed and Georgetown University Medical Center, USA, enter into a collaboration to develop a cancer research database.
2006 - December
Indivumed wins the competition to become a "Place in the Land of Ideas".
2005 - June
Indivumed is named “Germany’s Best Company” in the Visionary Category, winning the German Foundation Award 2005.
2004 - April
Indivumed's US subsidiary is founded with offices in Kensington, MD.
2003 - May
Indivumed is awarded “Best New Company” in Hamburg, Germany.
2002 - April
Founding of Indivumed in Hamburg, Germany, by Dr. Hartmut Juhl, Dr. Carsten Zornig, Dr. Peter Layer, and Frank Oertel. Bioagency AG provides start-up funding.
“At Indivumed we are united by a shared responsibility: using our unique expertise and skill sets to work toward individualized cancer diagnosis and treatment for every patient.”
Prof. Dr. med. Hartmut Juhl, Founder and CEO
Prof. Dr. med. Hartmut Juhl
Founder and Chief Executive Officer Indivumed Group
Prof. Dr. Hartmut Juhl is an entrepreneur, surgical oncologist, and world-renowned researcher dedicated to the science of tissue quality and its application to precision medicine in cancer diagnostics and therapeutics. He founded Indivumed to decipher the complexity of cancer and to enable truly personalized medicine.
Hartmut’s career started with studying medicine at the Hamburg-Eppendorf University Clinic from 1979 to 1986. He received his doctorate of medicine (Dr. med.) in 1989 and his “Habilitation” in Surgical Oncology in 1996.
Hartmut holds a professorship at the Medical Faculty of Hamburg University, is an adjunct professor at the Lombardi Cancer Center of Georgetown University, and has served as an advisor to the U.S. National Cancer Institute on matters of tissue quality for clinical and research applications.
He has led Indivumed since 2002 with a visionary entrepreneurial spirit. For this, he has received several awards of recognition.
For founding Indivumed GmbH in Hamburg he was awarded the Hamburg Foundation Prize in the category of “Founders of new Businesses” in 2003, as well as the German Foundation Prize in the category of “New Visionary” in 2005.
Together with scientists from Johns Hopkins University, Baltimore, Maryland, Hartmut participated in defining the first Liquid Biopsy technology to analyze circulation tumor DNA in plasma samples. For that, the AACR awarded Hartmut as part of the international multidisciplinary team for the concept of “liquid biopsies” for cancer, which has led to dramatic technological advancements in detecting cancer and has defined a new field in oncology.
Being first in commercializing this technology, Hartmut co-founded Inostics GmbH in 2008, as a subsidiary of Indivumed GmbH, jointly owned with scientists from Johns Hopkins University. Inostics was sold to Sysmex Corp. only three years after its foundation.
Since 2002, Hartmut has been leading the company with a clear vision – every step financially and strategically taken, from the beginning to now, from extending the advanced IndivuServ products and services to building IndivuType, the deepest oncology multi-omics database available today and IndivuTest, directly serving patients and oncologists with scientific data for better therapy selection. All this with the goal of realizing truly personalized medicine in mind.
Dr. Susanne Arbogast brings to Indivumed more than ten years of experience in implementing research and development programs in the field of (immuno-)oncology and individualized medicine. This is paired with her extensive expertise in global management of the interface between pharma and diagnostics as well as her broad external scientific network.
Susanne is a fully board-certified anatomical and surgical pathologist with an academic track record of over 15 years.
Prior to joining Indivumed, Susanne held various global senior leadership positions at Roche, where she drove discovery and clinical biomarker programs spanning pharma and diagnostics to enable personalized health-care treatment for patients.
Here, at Indivumed, she is responsible for the Indivumed Global Clinical Network, cooperating with numerous university and community clinics in Europe, the US, Asia, and South America, and continuously enhancing this network with her international team. By establishing and implementing the highest quality standard in accessing and collecting patient samples and clinical data, this network forms Indivumed’s basis to be able to foster an in-depth understanding of the molecular reality.
Dr. Nils Clausnitzer joined Indivumed in August 2019 as interim manager and executive consultant. He leads the IndivuServ Business Unit globally. Based on the company’s scientific roots, he and his team continuously expand IndivuServ’s high-quality sample (from FFPE to liquid biopsy) and service portfolio (ranging from IHC to digital pathology) to accelerate development activities for our customers and partners. He is head of the implementation of our “sample to analysis” strategy.
Nils started his career at the department of radiology at the University Hospital of Eppendorf in Hamburg, Germany, before moving into the industry. Over the last 17 years, Nils’s focus has been on change management to establish comprehensive and sustainable customer solutions in roles of growing responsibility.
Nils served as senior vice president and president of lab and distribution services of EMEA and was a member of the global executive management board at VWR/Avantor. Before that he served as president of sales and marketing of EMEA in Qiagen N.V., as managing director at Abbott GmbH & Co. KG, and as deputy managing director at Olympus Endoscopy Germany, Austria, and Switzerland.
Over the course of his professional life, Nils has gained experience across a number of functional areas including sales, marketing, product management, operations, commercial excellence, logistics, service, and business development in the medical technology and diagnostics industries. He studied medicine at the universities of Hamburg and Essen, Germany, and San Francisco, USA, and earned an MBA from the Open University, Milton Keynes, UK.
As the chief business officer and head of the IndivuType Business Unit, Roald Forsberg drives the strategic, operational, and commercial success of the IndivuType program.
Based on his extensive experience in bioinformatics, biotechnology, and advanced analytics, he is leading the development of the IndivuType AI platform and multi-omics data-processing infrastructure as well as the development of clinical integration and tumor sample processing. He works with his Business Development team to sell and deliver analysis projects and drug development partnership projects to accelerate personalized medicine in oncology.
Prior to joining Indivumed, Forsberg held several executive leadership positions at bioinformatics and biotechnology companies and worked in the field of management consulting.
Forsberg has driven deep-tech entrepreneurship and innovation and has worked extensively with the creation and successful implementation of digital business models in the life sciences sector.
Roald Forsberg has a PhD in bioinformatics and statistical genetics and has held research positions at the universities of Aarhus, Auckland, and Oxford.
Over the last 14 years, Alexandra has been involved in various international HR projects aimed at enhancing employee satisfaction at work and making global processes more digital and sustainable.
Alexandra started her career at TUI with an international graduate program through which she gained work experience in various countries. Throughout her career, she has held various HR positions in global organizations such as Olympus, EndoChoice, and TA Triumph-Adler. Alexandra has managed projects dealing with establishing expat policies, implementing HR systems, conducting engagement surveys, and reorganizing and scaling up companies.
She studied psychology with a focus on intercultural business communication, work and organizational psychology at the universities of Maastricht, Netherlands; Jena, Germany; and La Laguna, Spain, and has taken a MBA Essentials program at the London School of Economics and Political Science.
Alexandra Kroth is responsible for all people matters at Indivumed and supports the business especially in its international growth by establishing global procedures, policies, and an overall HR IT system.
As vice president of finance, Gudrun leads and coordinates the group’s financial planning, budgeting, accounting, and reporting requirements.
Before Gudrun joined Indivumed in November 2008, she had worked in several controlling and management positions in various industry segments. Since 1991 she has been working in an international business environment. She was the corporate controller of a German biotechnology company for nine years, where she supported the company’s IPO and was responsible for the headquarters and its subsidiaries.
Gudrun holds a master’s degree in business administration from Westfälische Wilhelms-University Münster. She also completed a stipendiary postgraduate program focused on small and medium-sized business at ITW Berlin.
She brings 30 years of professional experience in finance to Indivumed.
Nils Schumacher brings over 20 years of in-house legal and leadership experience to Indivumed, with a particular emphasis on IT- and data-driven environments.
Nils’s diverse work experience includes having served as a head of legal, an HR director, and a corporate secretary. Prior to joining Indivumed in 2017, Nils headed the legal departments of a VC/PE-financed multinational start-up and an international developer and distributor of software solutions and IT media and worked with an IT business consultancy and a US law firm.
As a qualified lawyer (degree from Friedrich-Alexander-University Erlangen and Bavarian state examinations) and admitted solicitor, Nils holds a European master’s degree in business mediation from IUKB Sion / University of Barcelona, as well as a degree in business administration from Hagen University.
Nils and his team ensure that all of Indivumed’s activities are faultless when it comes to regulatory demands and legal and compliance issues. Nils also serve as an additional contact for investor relations.
Indivumed has established close and long-standing partnerships with leading hospitals, clinics, and biopharma institutes in Europe, North America, and Asia.
The collaboration with these institutions is the basis for maintaining and expanding Indivumed’s high-quality biospecimens, clinical data, and breakthrough research techniques. Indivumed is continually expanding its clinical network in order to provide even better products and services for oncological drug discovery and development programs.